blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2680008

EP2680008 - Nrf2 screening assays and related methods and compositions [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  05.12.2014
Database last updated on 15.06.2024
Most recent event   Tooltip05.12.2014Application deemed to be withdrawnpublished on 07.01.2015  [2015/02]
Applicant(s)For all designated states
Biogen Idec MA Inc.
14 Cambridge Center
Cambridge, Massachusetts 02142 / US
[2014/01]
Inventor(s)01 / Lukashev, Matvey E.
3 Louis Road
Tewksbury, MA 01876 / US
02 / O'Neill, Gilmore
17 Grove Street
Medford, MA 02155 / US
 [2014/01]
Representative(s)Pohlman, Sandra M., et al
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstrasse 16
80333 München / DE
[N/P]
Former [2014/01]Pohlman, Sandra M., et al
df-mp Fünf Höfe Theatinerstrasse 16
80333 München / DE
Application number, filing date13179023.007.02.2008
[2014/01]
Priority number, dateUS20070888921P08.02.2007         Original published format: US 888921 P
[2014/01]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2680008
Date:01.01.2014
Language:EN
[2014/01]
Search report(s)(Supplementary) European search report - dispatched on:EP29.11.2013
ClassificationIPC:G01N33/68, G01N33/50
[2014/01]
CPC:
G01N33/502 (EP,US); A61K9/0065 (US); A61K31/137 (EP,US);
A61K31/194 (EP,US); A61K31/197 (EP,US); A61K31/225 (EP,US);
A61K31/277 (EP,US); A61K31/436 (EP,US); A61K31/4704 (EP,US);
A61K31/7076 (EP,US); A61K38/217 (EP,US); A61K45/06 (EP,US);
A61K9/28 (US); A61K9/4891 (US); A61P25/00 (EP);
A61P25/28 (EP); G01N33/5041 (US); A61K2300/00 (US);
G01N2333/90209 (EP,US); G01N2800/285 (EP,US) (-)
C-Set:
A61K31/194, A61K2300/00 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2014/01]
Extension statesALNot yet paid
BANot yet paid
MKNot yet paid
RSNot yet paid
TitleGerman:Nrf2-screening-Assays sowie entsprechende Verfahren und Zusammensetzungen[2014/01]
English:Nrf2 screening assays and related methods and compositions[2014/01]
French:Essais de criblage de Nrf2 et procédés et compositions correspondants[2014/01]
Examination procedure02.07.2014Application deemed to be withdrawn, date of legal effect  [2015/02]
07.08.2014Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time  [2015/02]
Parent application(s)   TooltipEP08725256.5  / EP2137537
EP13156663.0  / EP2629097
Fees paidRenewal fee
12.09.2013Renewal fee patent year 03
12.09.2013Renewal fee patent year 04
12.09.2013Renewal fee patent year 05
12.09.2013Renewal fee patent year 06
27.02.2014Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]  - SCHIMRIGK S ET AL, "Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study", EUROPEAN JOURNAL OF NEUROLOGY, (200606), vol. 13, no. 6, ISSN 1351-5101, pages 604 - 610, XP002496537 [X] 1-21 * the whole document *

DOI:   http://dx.doi.org/10.1111/j.1468-1331.2006.01292.x
 [X]  - SCHILLING S ET AL, "Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, (20060701), vol. 145, no. 1, doi:10.1111/J.1365-2249.2006.03094.X, ISSN 0009-9104, pages 101 - 107, XP009105979 [X] 1-21 * abstract *

DOI:   http://dx.doi.org/10.1111/j.1365-2249.2006.03094.x
 [X]  - GOLD R ET AL, "Safety of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study", JOURNAL OF NEUROLOGY - ZEITSCHRIFT FUER NEUROLOGIE, SPRINGER VERLAG, BERLIN, DE, (20060501), vol. 253, no. Suppl. 2, ISSN 0340-5354, pages II144 - II145, XP009157336 [X] 1-21 * the whole document *
 [X]  - KAPPOS L ET AL, "BG00012, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosis", MULTIPLE SCLEROSIS, SAGE PUBLICATIONS, BASINGSTOKE, GB, (20060101), vol. 12, no. Suppl. 1, ISSN 1352-4585, page S85, XP009157337 [X] 1-21 * abstract *
by applicantUS4851439
 US5149695
 US5650135
 US6217847
 US6451667
 WO2006037342
    - VAN MUISWINKEL, CURR. DRUG TARGETS CNS--NEUROL. DISORD., (2005), vol. 4, pages 267 - 281
    - MUISWINKEI ET AL., NEUROBIOL. AGING, (2004), vol. 25, page 1253
    - MUISWINKEL, CURR. DRUG TARGETS--CNS. NEUROL. DISORD., (2005), vol. 4, pages 267 - 281
    - VAN HORSSEN ET AL., FREE RADICAL BIOL. & MED., (2006), vol. 41, pages 311 - 311
    - SATOH, PNAS, (2006), vol. 103, no. 3, pages 768 - 773
    - MATTSON; CHENG, TRENDS IN NEUROSCI., (2006), vol. 29, no. 1 1, pages 632 - 639
    - SCHIMRIGK ET AL., EUR. J. NEUROL., (2006), vol. 13, no. 6, pages 604 - 10
    - DRUGS R&D, (2005), vol. 6, no. 4, pages 229 - 30
    - MITTOO, COMB. CHEM. & HIGH THROUGHPUT SCREEN, (2006), vol. 9, pages 429 - 423
    - DARLINGTON, CURR. OPIN. MOL. THER., (2005), vol. 7, no. 6, pages 598 - 603
    - WARREN ET AL., EUR. J. NEUROL., (2006), vol. 13, no. 8, pages 887 - 95
    - KWAK ET AL., J. BIOL. CHEM., (2003), vol. 278, page 8135
    - CHEN; KUNSCH, CURR. PHARM. DESIGNS, (2004), vol. 10, pages 879 - 891
    - LEE ET AL., J. BIOL. CHEM., (2003), vol. 278, no. 14, pages 12029 - 38
    - RUSHMORE ET AL., J. BIOL. CHEM., (1991), vol. 266, no. 18, pages 11632 - 9
    - NIOI ET AL., MUTATION RES., (2004), vol. 555, pages 14 - 171
    - DINKOVA-KOSTOVA ET AL., PNAS, (2005), vol. 102, no. 12, pages 4584 - 9
    - CHAN ET AL., PNAS, (1996), vol. 93, pages 13943 - 13948
    - KWAK ET AL., CELL. BIOL., (2002), vol. 22, no. 9, pages 2883 - 2892
    - KWAK ET AL., MOL. MED., (2001), vol. 7, pages 135 - 145
    - KRAFT ET AL., J. NEUROSCI, (2004), vol. 24, pages 1101 - 1112
    - SATOH ET AL., PNAS, (2006), vol. 103, no. 3, pages 768 - 773
    - CALABRESE ET AL., J. NEUROSCI. RES., (2005), vol. 79, pages 509 - 521
    - WIERINCKX ET AL., J. NEUROLMMUNOLOGY, (2005), vol. 166, pages 132 - 143
    - DINKOVA-KOSTOVA ET AL., PNAS, (2001), vol. 98, pages 3404 - 09
    - PROCHASKA ET AL., ANAL. BIOCHEM., (1988), vol. 169, pages 328 - 336
    - RAMOS-GOMEZ ET AL., J. NEUROSCI., (2004), vol. 24, no. 5, pages 1101 - 1112
    - HABIG ET AL., J. BIOL. CHEM., (1974), vol. 219, pages 7130 - 7139
    - KWAK ET AL., MOL. CELL BIOL., (2002), vol. 22, no. 9, pages 2883 - 2892
    - GAO ET AL., J. BIOL. CHEM.
    - SHIH ET AL., J. NEUROSCI., (2005), vol. 25, no. 44, pages 10321 - 35
    - MISGELD, HISTOCHEM. CELL BIOL., (2005), vol. 124, pages 189 - 196
    - LODLE ET AL., TISSUE ENG., (2002), vol. 8, no. 5, pages 739 - 751
    - HOFFMAN, LANCET ONCOL., (2002), vol. 3, pages 546 - 556
    - TUNG ET AL., CANCER RES., (2000), vol. 60, pages 4953 - 4958
    - SHI ET AL., PNAS, (2001), vol. 98, pages 12754 - 12759
    - LUKE ET AL., J. VIROL., (2002), vol. 76, pages 12149 - 12161
    - LIANG ET AL., MOL. THER., (2002), vol. 6, pages 73 - 82
    - HEMMINKI ET AL., J. NAT. CANCER INST., (2002), vol. 94, pages 741 - 749
    - TUOHY ET AL., J. LMMUNOL., (1988), vol. 141, pages 1126 - 1130
    - SOBEL ET AL., J. IMMUNOL., (1984), vol. 132, pages 2393 - 2401
    - TRAUGOTT, CELL IMMUNOL., (1989), vol. 119, pages 114 - 129
    - BAKER ET AL., J. NEUROIMMUNOL., (1990), vol. 28, page 261
    - BUTTER ET AL., J. NEUROL. SCI., (1991), vol. 104, page 9
    - HARRIS ET AL., ANN. NEUROL., (1991), vol. 29, page 648
    - KERMONDE ET AL., BRAIN, (1990), vol. 113, page 1477
    - BEN-NUN ET AL., EUR. J. IMMUNOL., (1981), vol. 11, pages 195 - 199
    - ANDO ET AL., CELL IMMUNOL., (1989), vol. 124, pages 132 - 143
    - ZAMVIL ET AL., NATURE, (1985), vol. 317, pages 355 - 358
    - ZAMVIL ET AL., ANN. REV. IMMUNOL., (1990), vol. 8, pages 579 - 621
    - TUOHY ET AL., J. IMMUNOL., (1988), vol. 141, pages 1126 - 1130
    - ERCOLI ET AL., J. LMMUNOL., (2006), vol. 175, pages 3293 - 3298
    - UNER ET AL., J. AUTOIMMUNE DISEASE, (1998), vol. 11, no. 3, pages 233 - 240
    - JI ET AL., LMMUNOL. REV., (1999), vol. 69, page 139
    - RIEMEKASTEN ET AL., ARTHRITIS RHEUM., (2001), vol. 44, no. 10, pages 2435 - 2445
    - BAXTER ET AL., AUTOIMMUNITY, (1991), vol. 9, no. 1, pages 61 - 67
    - LINKER ET AL., EUR. J. IMMUNOL., (2002), vol. 8, no. 6, pages 620 - 624
    - EUGSTER ET AL., NAT. MED., (1999), vol. 29, pages 626 - 632
    - GOLD ET AL., BRAIN, (2006), vol. 129, pages 1953 - 1971
    - FREIREICH ET AL., CANCER CHEMOTHER. REPORTS, (1966), vol. 50, no. 4, pages 219 - 244
 US20040511564
 US20060421083
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.